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Abstract
Introduction: Cancer and infections are leading causes of mortality in systemic lupus erythematosus (SLE) after 
diseases of the circulatory system, and therefore preventing these complications is important. In this study, we 
examined two categories of preventive services in SLE: cancer surveillance (cervical, breast, and colon) and 
immunizations (influenza and pneumococcal). We compared the receipt of these services in SLE to the general 
population, and identified subgroups of patients who were less likely to receive these services.
Methods: We compared preventive services reported by insured women with SLE enrolled in the University of 
California, San Francisco Lupus Outcomes Study (n = 685) to two representative samples derived from a statewide 
health interview survey, a general population sample (n = 18,013) and a sample with non-rheumatic chronic 
conditions (n = 4,515). In addition, using data from the cohort in both men and women (n = 742), we applied 
multivariate regression analyses to determine whether characteristics of individuals (for example, sociodemographic 
and disease factors), health systems (for example, number of visits, involvement of generalists or rheumatologists in 
care, type of health insurance) or neighborhoods (neighborhood poverty) influenced the receipt of services.
Results: The receipt of preventive care in SLE was similar to both comparison samples. For cancer surveillance, 70% of 
eligible respondents reported receipt of cervical cancer screening and mammography, and 62% reported colon cancer 
screening. For immunizations, 59% of eligible respondents reported influenza immunization, and 60% reported 
pneumococcal immunization. In multivariate regression analyses, several factors were associated with a lower 
likelihood of receiving preventive services, including younger age and lower educational attainment. We did not 
observe any effects by neighborhood poverty. A higher number of physician visits and involvement of generalist 
providers in care was associated with a higher likelihood of receiving most services.
Conclusions: Although receipt of cancer screening procedures and immunizations in our cohort was comparable to 
the general population, we observed significant variability by sociodemographic factors such as age and educational 
attainment. Further research is needed to identify the physician, patient or health system factors contributing to this 
observed variation in order to develop effective quality improvement interventions.
Introduction
Over the last several decades, the prognosis of patients
with systemic lupus erythematosus (SLE) has improved
dramatically, with five-year survival now above 95% in
developed countries [1]. This increased survival has
necessitated adjustment of clinical care for this popula-
tion, with the complications and co-morbidities of the
disease gaining greater attention. Infection and malig-
nancy are the two leading causes of mortality in SLE after
diseases of the circulatory system [1]. We sought to
examine receipt of several preventive services that may
influence these outcomes in a large, community-based
cohort of individuals with SLE.
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chronic diseases may receive fewer preventive services
than the general population [2-5]. In the rheumatic dis-
eases, studies examining cancer screening in rheumatoid
arthritis and SLE have yielded similar results [2,5]. The
reasons for these findings remain unclear, but hypotheses
include that management of the primary disease may
dominate provider and patient time, responsibility for
preventive services may span several physicians and spe-
cialties, and resources may be limited - both in terms of
patient time and because chronically ill patients are often
underinsured [6]. In SLE, factors specific to the condi-
tion, such as the unpredictable nature of disease exacer-
bations and concerns about vaccine safety in
immunocompromised hosts, may also potentially hinder
attention to preventive services.
In this study, we sought to examine two categories of
preventive services: cancer surveillance (cervical, breast,
and colon) and immunizations (influenza and pneumo-
coccal). We compared the receipt of preventive services
in SLE to the general population, and identified specific
subgroups of patients with SLE who are less likely to
receive these services. In addressing this latter aim, we
attempted to examine not only characteristics of individ-
uals (for example, sociodemographic and disease related
factors), but also characteristics of health systems (for
example, number of outpatient visits, involvement of gen-
eralist providers or rheumatologists in patient care, type
of health insurance) and characteristics of neighborhoods
(that is, neighborhood poverty level).
Materials and methods
Data sources
LOS
Data were derived from the University of California, San
Francisco (UCSF) Lupus Outcomes Study (LOS), a longi-
tudinal observational study of 1,179 English-speaking
individuals with SLE. Details on study methodology have
been reported previously [7]. Briefly, study respondents
participate in an annual telephone survey, providing
information about their demographic characteristics,
socioeconomic status, medications, disability, general
health and social functioning, health care utilization,
health insurance coverage, and disease activity [7].
Recruitment for the study took place in several settings in
an attempt to capture the full spectrum of SLE, including
academic rheumatology offices (23%), community rheu-
matology offices (11%), and community-based sources
such as SLE support groups, the Internet, and media
advertisements (66%). All patients have carried a diagno-
sis of SLE from a physician, and we further confirmed
these diagnoses by a formal review of the medical record
to document American College of Rheumatology Criteria
for SLE [8].
Items regarding receipt of preventive health services
were introduced in the fourth annual LOS interview, con-
ducted between March 2005 and February 2006; 797
individuals participated in that interview. Of the 797, 14
(2%) were excluded from the sample. Four individuals
were excluded because they resided outside the United
States at the time of the interview. Ten individuals were
excluded because they reported having no health insur-
ance; this group was too small to make robust conclu-
sions regarding lack of insurance. Of the remaining 783
individuals, 5% were dropped from the sample because of
the following missing data: below poverty status (n = 10;
1%); HMO (n = 18, 2% did not know if they were in a
HMO or not); area poverty level (n = 13; 2% lived in areas
with no geocoded data either because they resided in new
residential areas that were developed after the 2000 Cen-
sus was conducted, or because they had moved since the
geographic match was performed). For the analysis com-
paring LOS service receipt to population controls
(described below), we included 685 of these respondents;
men were excluded (n = 57) to facilitate comparisons
with the controls. For the second part of the study exam-
ining predictors of receipt of preventive services, men
were included, yielding a total sample of 742 individuals.
CHIS
For the population comparison, we analyzed primary
data from the California Health Interview Survey (CHIS),
a random-digit-dial telephone survey administered to
households in California [9]. The CHIS sample is repre-
sentative of California's non-institutionalized popula-
tion. We chose CHIS because the survey included all the
variables of interest, and because a majority of LOS
respondents reside in California. Response rates of CHIS
are comparable to other statewide telephone surveys
(approximately 49.8% among adults interviewed in 2005).
We report receipt of preventive services in the LOS com-
pared to two subsamples of CHIS. The first included the
overall CHIS sample as a general population comparison,
and the second included only CHIS respondents report-
ing chronic medical conditions (asthma, diabetes melli-
tus, or heart disease). Among the 4,515 individuals with
chronic diseases, 1,595 (35%) had asthma, 3,399 (75%)
had diabetes, and 3,255 (72%) had heart disease.
For most preventive services, we analyzed CHIS inter-
views from the same calendar year as these services were
queried from LOS respondents (2005). However, for
pneumococcal immunization, we used CHIS data from
2003, the most recent year in which data on this service
were available. To more closely approximate the LOS
population, we included only data from CHIS respon-
dents ≥ 18 years, who spoke English, were female and
reported having health insurance. This resulted in a sam-
ple size of 18,013 for the CHIS general population com-
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condition comparison.
Measures
We examined receipt of five preventive care services,
including cancer screenings (mammography, colon can-
cer screening, and cervical cancer screening), and immu-
nizations (influenza and pneumococcal). For cancer
screening, we evaluated receipt of care advocated by the
United States Preventive Services Task Force recommen-
dations [10]. We examined screening mammography
over the previous year in women ≥ 40 years with no his-
tory of breast cancer. Cervical cancer screening was
examined in the previous year among women 18 to 65
years who did not report a hysterectomy and had no his-
tory of cervical cancer. Colon cancer screening (defined
as a colonoscopy in the last 10 years or a flexible sigmoi-
doscopy plus fecal occult blood in the last five years) was
examined in those ≥ 50 years with no history of colorectal
cancer.
We used the Centers for Disease Control (CDC) rec-
ommendations and the recently developed quality indica-
tors for SLE to determine eligibility for immunizations
[11-13]. We examined influenza immunization in the
previous year among individuals receiving immunosup-
pressive therapy or age ≥ 50 years. For pneumococcal
immunization, we determined whether individuals
receiving immunosuppressive therapy or those ≥ 65 years
had ever received the vaccine.
We applied the same inclusion and exclusion criteria to
the CHIS data. For immunizations, eligibility for the
CHIS general population was defined by age (≥ 50 years
for influenza, and ≥ 65 years for pneumococcal). For the
CHIS population reporting chronic medical conditions,
all respondents were considered eligible for influenza
immunization, and those ≥ 50 years were considered eli-
gible for pneumococcal vaccine (the CHIS survey only
queries receipt of pneumococcal vaccine in those ≥ 50
years).
We considered factors previously associated with
receipt of preventive services as potential covariates
when examining predictors of receipt of preventive ser-
vices in the LOS. These included sociodemographic fac-
tors such as age, sex, race/ethnicity (Caucasian versus
other), education (high school education or less, some
college, or college graduate), and poverty (household
income less than 125% of the Federal poverty threshold).
To examine the influence of disease status, we used the
Systemic Lupus Activity Questionnaire (SLAQ), a self-
report instrument [14,15], and the Short Form-36 Physi-
cal Functioning Scale (SF-36) [16].
Because we were interested in whether health care
access variables influence the receipt of preventive care,
we also considered: 1) the total number of physician visits
over the last year; 2) whether a generalist provider was
involved in care (including all physicians or nurse practi-
tioners functioning as primary care providers); 3)
whether a rheumatologist was involved in care; 4) the
type of health insurance used (public health insurance,
including Medicare or Medicaid, or private health insur-
ance, including employer-based plans). The health insur-
ance variables were further stratified by enrollment in a
health maintenance organization (HMO), given that
some HMOs, particularly prepaid group practices, place
special emphasis on preventive care [17,18].
Previous research suggests that community character-
istics may hinder access to preventive care in some popu-
lations [19]. We therefore evaluated whether a contextual
variable, neighborhood poverty, influenced receipt of
preventive care services. To obtain information about
study participants' neighborhood poverty, data from the
2000 U.S. Census were matched to participants' residen-
tial addresses through a process known as geocoding,
described in detail elsewhere [20]. Geocoding procedures
were conducted using the Environmental Systems
Research Institute ArcGIS software by Sonoma Technol-
ogy (Petaluma, CA, USA).
All respondents provided informed consent to partici-
pate in the study. The UCSF Committee on Human
Research approved the study protocol.
Statistical analysis
We compared unadjusted frequencies of receiving pre-
ventive services in the LOS to the two CHIS samples. We
used SUDAAN 10.0 (Research Triangle Park, NC, USA)
in order to account for the CHIS sampling design.
Because the samples differed significantly in terms of age
and education, we calculated age and education stan-
dardized estimates from CHIS to reduce confounding.
We used multivariate logistic regression models to
examine whether specific subgroups of patients in the
LOS were less likely to receive each preventive service.
Each of the models included demographic factors, health
care access factors, health status, and neighborhood pov-
erty level. We used SAS 9.2 (SAS Institute, Cary, NC,
USA) for this portion of the analysis.
In addition to examining each preventive service indi-
vidually, we were also interested in examining the overall
quality of preventive care in the LOS. We therefore devel-
oped pass frequencies [21] (defined as the percentage of
times that each service was received among eligible indi-
viduals) for the two immunizations, three cancer screen-
ing procedures, and all five of these services combined. In
these analyses, respondents contributed one observation
for each eligible service, and thus there were between one
and five observations per respondent. We accounted for
these repeated measures in our regression models. We
present the adjusted pass frequencies from these models,
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receiving preventive services controlling for all of the
other variables of interest. This analysis was completed in
SUDAAN 10.0.
Results
Patient characteristics
The characteristics of subjects enrolled in the LOS and
CHIS are listed in Table 1. To facilitate comparisons with
CHIS, males were excluded from the comparative analy-
sis between the two samples (the LOS analysis sample
consists of 685 women and 57 men). Both samples are
primarily Caucasian (among individuals included in the
LOS analysis, 68% were Caucasian, 9% Latino, 7% Afri-
can-American, 8% Asian/Pacific Islander, and 6% other;
among individuals in CHIS, 75% were Caucasian, 9%
Latino, 5% African-American, 7% Asian/Pacific Islander,
and 4% other). The number of individuals living below
poverty was similar between the samples. Although levels
of college education were comparable between the two
samples, LOS respondents reported higher educational
attainment overall. A similar percentage of individuals in
the two samples were enrolled in Medicaid. However, a
higher percentage of LOS respondents report Medicare
coverage. In the LOS, 19% of individuals reported having
no primary care provider, and 16% reported that a rheu-
matologist was not involved in care. Respondents had a
mean of 16 physician visits per year.
Receipt of preventive health services in the LOS versus CHIS
Table 2 summarizes the percentage of eligible patients
enrolled in the LOS and CHIS who received recom-
mended cancer screening and immunizations. We found
that the crude frequency of receipt of services in persons
with SLE was comparable to the general population for
almost all services examined, with the exception of
receipt of pneumococcal immunization. LOS respon-
dents were less likely to report pneumococcal immuniza-
tion than the CHIS general population, but frequencies
were similar to those with chronic conditions enrolled in
CHIS. Those enrolled in CHIS were less likely to receive
influenza immunization than LOS respondents. In addi-
tion to examining the crude frequencies reported in Table
2, we also standardized the LOS sample to CHIS by age
and education. These standardized frequencies yielded
the same conclusions as those discussed above.
Predictors of receipt of individual preventive health 
services in the LOS
Consistent with previous literature on the receipt of pre-
ventive health services in the general medical population,
different predictors were identified for the different ser-
vices examined (Table 3). Older individuals were more
likely to receive four of the services: influenza immuniza-
tion, pneumococcal immunization, colon cancer screen-
ing and mammography. Race/ethnicity did not predict
the receipt of most services, except that non-Caucasian
LOS respondents were more likely to report mammogra-
phy. Those with a college education were more likely to
receive most services, although this only reached statisti-
cal significance for cervical cancer screening and immu-
nizations. Individuals living below poverty were less likely
to receive cervical cancer screening. Although enrollment
in an HMO did influence receipt of preventive services,
the findings varied across services. For example, those
enrolled in HMOs appeared more likely to receive immu-
nizations, but less likely to receive cancer screening.
Those reporting a visit to a generalist physician in the
last year were more likely to receive many of the preven-
tive services examined (influenza and pneumococcal
immunizations, cervical cancer screening). Individuals
seeing a rheumatologist in the last year were more likely
to receive influenza immunizations. Total physician visits
increased the likelihood of receiving services, reaching
statistical significance for all cancer screening tests. More
disease activity, as measured by the SLAQ, was associated
with fewer immunizations, as was higher physical func-
tioning. We did not see any significant effects by neigh-
borhood poverty level once personal socioeconomic
status was taken into account.
Predictors of receipt of overall preventive health services in 
the LOS
Table 4 lists the pass frequencies for immunizations, can-
cer screening tests, and all preventive services combined
in the LOS. The first sample of 1,117 observations repre-
sents patients who were eligible for either influenza or
pneumococcal immunizations. Since one person may be
eligible for both, this sample includes repeated measures.
The sample in the second column represents 1,364 obser-
vations eligible for colon cancer screening, mammogra-
phy or cervical cancer screening. The last sample of 2,481
observations combines the previous two samples to rep-
resent all observations eligible for preventive services.
As demonstrated in the last column, the frequency of
receiving preventive services increased with age but no
differences were noticed between men and women, by
income, or by race/ethnicity. The frequency of receiving
preventive services also increased with higher educa-
tional attainment. Having a generalist physician involved
in clinical care increased the likelihood of receiving pre-
ventive services, as did the total number of outpatient
physician visits. Having a rheumatologist involved in care
increased the likelihood of receiving immunizations.
Those with managed care and public insurance have
higher immunization frequencies but lower frequencies
of cancer screening. Cancer screening was more likely for
those with private insurance. Lastly, increased SLAQ
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Page 5 of 10Table 1: Characteristics of women in the Lupus Outcomes Study (LOS) and the California Health Interview Survey (CHIS)
Characteristic LOS N = 685 CHIS N = 18,013 CHIS, with chronic 
conditions* N = 4,515
Sociodemographics
Age, mean (SD) 50.1 (12) 44.0 (16) 48.7 (28)
Race/Ethnicity, n (%)
Caucasian 468 (68) 13,544 (63) 3,464 (66)
Non-caucasian 217 (32) 4,469 (37) 1,051 (34)
Education, n (%)
<High school or High school graduate 95 (14) 4,810 (32) 1,384 (36)
Some college 322 (47) 5,522 (29) 1,535 (32)
College 268 (39) 7,681 (39) 1,596 (33)
Below Poverty, n (%)
No 602 (88) 4,068 (90) 16,812 (92)
Yes 83 (12) 447 (10) 1,201(8)
Health Care Access
Insurance, n (%)
Medicaid 33 (6) 849 (5) 338 (7)
Medicare 260 (38) 2,012 (7) 774 (13)
Private/Employer 392 (57) 15,152 (88) 3,403 (81)
Insurance category, n (%)
HMO and public insurance (Medicare or Medicaid) 61 (9) 230 (2) 68 (2)
HMO and private insurance 153 (22) 7,967 (52) 1,743 (47)
No HMO and public insurance (Medicare or Medicaid) 235 (34) 2,631 (10) 1,044 (17)
No HMO and private 242 (35) 7,185 (37) 1,660 (34)
Physicians
Generalist involved in health care, n (%) 557 (81)
Rheumatologist involved in health care, n (%) 573 (84)
Total number of physician visits in one year, mean (SD) 16.0 (10.4)
Health status
SLAQ score, mean (SD) 13.0 (8)
SF-36 Physical Function, mean (SD) 57.7 (29)
Contextual Factor
Neighborhood Poverty, n (%)
No 627 (92)
Yes 58 (8)
*Chronic conditions examined in CHIS include self-reported diabetes mellitus, asthma or heart disease.
Abbreviations: LOS, Lupus Outcomes Study; CHIS, California Health Interview Survey; HS, high school; SLAQ, Systemic Lupus Activity 
Questionnaire; SF-36, Short-Form 36 Health Survey; HMO, health maintenance organization.
scores and higher SF-36 physical function scores were
associated with lower immunization frequencies. We did
not observe a difference in the receipt of preventive ser-
vices by neighborhood poverty level.
Discussion
Although the overall receipt of cancer screening proce-
dures and immunizations in the UCSF LOS was relatively
high and comparable to the general population, we
observed considerable variation among sociodemo-
graphic subgroups. In particular, individuals with SLE
who were younger and reported less educational attain-
ment were significantly less likely to receive preventive
services. In addition, health system factors, such as the
involvement of a generalist provider in care and total phy-
sician visits, were also associated with the receipt of pre-
ventive health care services in SLE.
Although immunization frequencies in SLE have not
previously been reported, our finding that about 60% of
eligible patients receive pneumococcal or influenza
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matic diseases [22]. The finding that 40% of patients
remain unvaccinated is notable given that approximately
one-third of deaths in SLE are attributable to infections
[23], and several studies have found that respiratory
infections, including those attributable to Streptococcus
pneumoniae, are the leading cause of serious infections in
SLE [24,25]. We did not investigate specific reasons for
non-immunization, which might include patient prefer-
ences, contraindications, failure of providers to offer the
vaccine, or cost. In SLE, suboptimal immunization fre-
quencies may also partly reflect long-standing concerns
about vaccine safety that arose after early reports of fatal-
ities or increased disease activity following immunization
[26,27]. However, several decades of scientific research
have now failed to corroborate these early concerns [28].
Based on this evidence, recently developed quality indica-
tors for SLE have established influenza and pneumococ-
cal immunization in this population as a minimally
acceptable standard of care [13]. Our study suggests that
individuals with lower educational attainment are at par-
ticularly high risk of not receiving immunizations, a find-
ing that is consistent with a growing body of evidence
that individuals with less education may receive poorer
quality health care [29,30].
About one third of patients in our cohort did not
receive recommended cancer screening tests. As in the
case with immunizations, younger patients and those
with less educational attainment were less likely to
receive recommended cancer screening. Although we
expected that those enrolled in HMOs would be more
likely to receive cancer screening given the emphasis of
these organizations on preventive care, this was not the
case. However, consistent with other recent studies, indi-
viduals with a higher number of physician visits were
more likely to receive cancer screening services [31,32].
No specific cancer surveillance guidelines for SLE have
been published to date, although at a minimum, it seems
reasonable that SLE patients should receive cancer sur-
veillance tests recommended for the general population.
One previous study has examined cancer surveillance
rates in Canadian SLE patients using a tertiary-care clinic
cohort. In that study, researchers surveyed 146 patients
regarding receipt of cancer screening tests in the last year.
Unlike our study that found screening rates similar to the
general population, rates in that cohort fell well below
general population cancer screening rates in Canada [5].
Our study also suggests that both a higher number of
physician visits and involvement of primary care provid-
ers in SLE management are associated with improved
preventive health care quality. As short-term mortality
from SLE declines and clinical care increasingly shifts
toward the long-term prevention and management of co-
morbidities and complications, effectively coordinating
care between specialists and primary care providers is a
priority. Such coordination, however, may prove chal-
lenging in SLE, where clinical care often spans multiple
specialists who sometimes practice at significant geo-
Table 2: Receipt of preventive services by women in the Lupus Outcomes Study and the general population
Service (LOS eligible group) LOS 2005 CHIS 2005§ CHIS 2005 §, with chronic 
conditions
N (%) 95% CI N (%) 95% CI N (%) 95% CI
Cervical cancer screening1 (women ≥ 65 
years with a uterus)*
302 (70) 66 to 74 9,283 (73) 72 to74 1,917(74) 71 to 76
Mammogram2 (≥ 40 years)* 384 (70) 67 to 74 8,875 (68) 67 to 69 2,449 (69) 67 to 71
Colon Cancer3 (≥ 50 years)* 221(62) 57 to 67 5,355 (57) 55 to 58 1,688 (59) 56 to 61
Influenza vaccine4 (≥ 50 years or 
immunosuppressed)†
338 (59) 55 to 63 4,010 (42) 40 to 43 2,016 (38) 36 to 40
Pneumococcal vaccine5 (≥ 65 years or 
immunosuppressed)†
272 (60) 56 to 65 3,074 (70) 68 to 72 1,756 (57) 54 to 60
§All data are from CHIS 2005, except for pneumococcal vaccine, for which the most recent CHIS data are from 2003. Chronic conditions 
examined in CHIS include self-reported diabetes mellitus, asthma or heart disease.
1. Compared to CHIS respondents 18 to 65 years with a uterus and no history of cervical cancer with health insurance.
2. Compared to CHIS ≥ 40 years, with no history of breast cancer with health insurance.
3. Compared to CHIS ≥ 50 years, with no history of colon cancer with health insurance.
4. Compared to the CHIS respondents ≥ 50 years with health insurance. For the CHIS sample with chronic conditions, all ages were considered 
eligible for the vaccine.
5. Compared to the CHIS general population age ≥ 65 with health insurance. For the CHIS sample with chronic conditions, immunization 
information was available for respondents ≥ 50 years.
*United States Preventive Services Task Force guidelines.
†Centers for Disease Control and Prevention guidelines.
Abbreviations: LOS, Lupus Outcomes Study; CHIS, California Health Interview Survey.
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Page 7 of 10Table 3: Predictors of receiving preventive services in men and women enrolled in the Lupus Outcomes Study
Immunizations Cancer Screening
Influenza Vaccine 
(n = 626)
Pneumococc al 
Vaccine (n = 491)
Colon Cancer 
Screening (n = 389)
Mammogram 
(n = 545)
Cervical cancer 
Screenin g (n = 430)
Odds Ratio (95% CI)
Sociodemographics
Age (per 10 units) 1.3 (1.1, 1.5) 1.4 (1.2, 1.7) 1.7 (1.2, 2.5) 1.4 (1.1, 1.8) 1.2 (1.0, 1.5)
Female 1.1 (0.6, 2.1) 1.1 (0.5, 2.2) 0.5 (0.2, 1.2) -- --
Non-White 0.7 (0.5, 1.1) 0.7 (0.4, 1.1) 0.8 (0.5, 1.4) 1.6 (1.0, 2.6) 1.2 (0.7, 2.0)
Education
High School Graduate 0.7 (0.4, 1.3) 0.9 (0.4, 1.7) 0.9 (0.4, 1.9) 1.3 (0.7, 2.6) 1.5 (0.7, 3.4)
Some College 0.5 (0.3, 0.8) 0.5 (0.2, 0.9) 0.8 (0.4, 1.5) 0.8 (0.4, 1.4) 0.4 (0.2, 0.9)
College Graduate (referent)
Income
Below Poverty 0.7 (0.5, 1.1) 0.8 (0.5, 1.2) 0.9 (0.5, 1.5) 1.0 (0.6, 1.5) 0.4 (0.2,0.6)
Health Care Access
Insurance
HMO and Public Insurance (Medicaid, 
Medicare)
2.5 (1.2, 5.3) 4.5 (1.8, 11.3) 0.4 (0.2, 1.0) 0.7 (0.3, 1.4) 0.4 (0.2, 1.1)
HMO and Private 0.9 (0.6, 1.5) 2.0 (1.1, 3.4) 0.5 (0.2, 0.8) 0.8 (0.5, 1.4) 0.4 (0.2, 0.6)
Insurance
No HMO, Public 0.9 (0.5 to 1.4) 1.5 (0.9 to 2.6) 0.7 (0.3, 1.2) 0.6 (0.4, 1.1) 0.4 (0.2, 0.8)
Insurance (Medicaid, Medicare)
No HMO, Private Insurance (referent)
Physician Visits
Generalist involved in health care 1.6 (1.0, 2.5) 1.8 (1.0, 3.0) 0.6 (0.3, 1.1) 1.5 (0.9, 2.5) 2.2 (1.3, 3.7)
Rheumatologist involved in health 
care
2.3 (1.4, 3.8) 1.5 (0.8, 2.9) 0.8 (0.4, 1.5) 1.4 (0.8, 2.3) 1.0 (0.5, 2.0)
Total physician visits (per five visits) 1.1 (1.0, 1.2) 1.1 (1.0, 1.3) 1.3 (1.1, 1.5) 1.2 (1.0, 1.3) 1.2 (1.0. 1.4)
Health Status
SLAQ Score (per 10 units) 0.7 (0.5, 1.0) 0.7 (0.5, 1.0) 1.2 (0.8, 1.8) 1.0 (0.8, 1.4) 1.2 (0.8, 1.7)
SF-36 Physical Function (per 10 units) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 1.0 (0.9, 1.1) 1.2 (1.1, 1.3) 1.2 (1.1, 1.3)
Contextual Factor
Neighborhood Poverty Area 1.4 (0.7, 2.5) 1.2 (0.6, 2.4) 2.2 (0.9, 5.4) 0.9 (0.4, 1.7) 1.6 (0.6, 4.1)
Abbreviations: SLAQ, Systemic Lupus Activity Questionnaire; SF-36, Short-Form 36 Health Survey; HMO, Health Maintenance Organization. Bolded 
values indicate P < 0.05.
graphic distances from each other [33,34]. Increasing
awareness among primary care providers about the
higher risk of specific long-term complications in SLE,
and improving care coordination by specialists caring for
SLE patients through various practice innovations, such
as automatic reminders in electronic medical records,
may help improve the quality of preventive health care in
this population.
Studying health services in SLE is challenging given the
low prevalence of the disease. Most research to date has
drawn from tertiary care specialty clinics, which may not
adequately represent the entire population with SLE.
Although not a random sample of the population of
patients with SLE, our study has attempted to partly
address this gap by drawing from community-based
sources. Nevertheless, our study has limitations. First,
because the LOS participants speak English and have
health insurance, we cannot generalize our findings to
non-English speaking individuals or those without health
insurance - two groups that are at great risk of receiving
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Immunizations (n = 1117) Cancer Screening (n = 1364) All Services (n = 2481)
Sociodemographics Percent (95% CI)
Age
18 to 34 0.42 (0.32,0.52) 0.63 (0.52,0.74) 0.48 (0.40,0.56)
35 to 54 0.58 (0.54,0.63) 0.65 (0.61, 0.70) 0.62 (0.59, 0.66)
55 to 64 0.59 (0.52,0.65) 0.70 (0.66,0.75) 0.66 (0.62,0.70)
65+ (referent) 0.72 (0.64,0.81) 0.76 (0.70,0.83) 0.75 (0.69,0.80)
Gender
Female 0.57 (0.47, 0.67) 0.73 (0.59, 0.88) 0.60 (0.51, 0.69)
Male (referent) 0.59 (0.56, 0.63) 0.68 (0.65, 0.71) 0.64 (0.62, 0.67)
Education
HS Grad or less 0.47 (0.38,0.57) 0.63 (0.56,0.71) 0.57 (0.51,0.64)
Some College 0.58 (0.53,0.62) 0.66 (0.61,0.70) 0.62 (0.59,0.65)
College (referent) 0.64 (0.59,0.69) 0.73 (0.69,0.77) 0.69 (0.65,0.73)
Race/Ethnicity
White 0.61 (0.57, 0.65) 0.67 (0.64, 0.71) 0.65 (0.62, 0.68)
Non-White (referent) 0.54 (0.48, 0.60) 0.70 (0.65, 0.75) 0.62 (0.59, 0.66)
Income
Above Poverty 0.60 (0.56,0.63) 0.68 (0.65,0.71) 0.64 (0.62,0.67)
Below Poverty (referent) 0.54 (0.44, 0.64) 0.72 (0.64, 0.79) 0.64 (0.57, 0.71)
Health Care Access
Insurance
HMO with Public Insurance (Medicare, Medicaid) 0.77 (0.68, 0.87) 0.63 (0.53, 0.73) 0.69 (0.62, 0.76)
HMO with Private Insurance 0.60 (0.54, 0.67) 0.63 (0.57, 0.69) 0.62 (0.57, 0.66)
No HMO, Public Insurance (Medicare, Medicaid) 0.57 (0.51, 0.63) 0.66 (0.60, 0.72) 0.62 (0.57, 0.66)
No HMO, Private Insurance (referent) 0.56 (0.50, 0.62) 0.76 (0.71, 0.80) 0.67 (0.63, 0.71)
Generalist Involved in Care
Generalist (referent) 0.61 (0.57, 0.65) 0.69 (0.66, 0.72) 0.66 (0.63, 0.68)
No Generalist 0.50 (0.43, 0.58) 0.64 (0.57, 0.71) 0.58 (0.52, 0.64)
Rheumatologist Involved in Care
Rheumatologist (referent) 0.61 (0.57, 0.64) 0.69 (0.66, 0.72) 0.65 (0.63, 0.67)
No Rheumatologist 0.47 (0.38, 0.55) 0.67 (0.61, 0.74) 0.59 (0.53, 0.65)
Total Outpatient Physician Visits*
Fewer visits (mean - 1 SD) (5.5) 0.54 (0.48, 0.59) 0.61 (0.56, 0.66) 0.58 (0.54, 0.62)
Mean visits (15.8) 0.58 (0.55, 0.62) 0.69 (0.66, 0.71) 0.64 (0.62, 0.66)
More visits (mean + 1 SD) (26.2) 0.63 (0.58, 0.68) 0.75 (0.71, 0.80) 0.70 (0.66, 0.73)
Health Status
SLAQ Score*
Score at mean - 1 SD (4.7) 0.65 (0.60, 0.70) 0.67 (0.62, 0.72) 0.66 (0.62, 0.70)
Score at mean (12.6) 0.59 (0.56, 0.63) 0.68 (0.65, 0.71) 0.64 (0.62, 0.66)
Score at mean + 1 SD (20.5) 0.53 (0.48, 0.58) 0.70 (0.66, 0.74) 0.62 (0.59, 0.66)
SF-36 Physical Function*
Score at mean (58.6) 0.58 (0.55, 0.62) 0.69 (0.66, 0.71) 0.69 (0.66, 0.71)
Score at mean + 1 SD (88.0)
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Page 9 of 10Contextual Factor 0.49 (0.43, 0.55) 0.74 (0.70, 0.78) 0.74 (0.70, 0.78)
Neighborhood Poverty
No (referent) 0.59 (0.55, 0.62) 0.68 (0.65, 0.71) 0.64 (0.61, 0.66)
Yes 0.63 (0.53, 0.73) 0.74 (0.65, 0.83) 0.69 (0.63, 0.76)
Values represent adjusted pass frequencies from multivariate logistic regression models, which provide estimates of the probability of individuals 
receiving services after controlling for the other variables listed. Bolded values indicate P < 0.05. Abbreviations: SLAQ, Systemic Lupus Activity 
Questionnaire; SF-36, Short-Form 36 Health Survey.
*These were continuous variables in the regression models; pass frequencies represent the values at the mean score for the variable, and one 
standard deviation above and below the mean.
Table 4: Adjusted pass frequencies for receipt of preventive services by men and women in the Lupus Outcomes Study 
poorer quality health care. Conducting this research in Competing interests
non-English speaking and indigent populations should be
prioritized in future studies. Second, participants in the
LOS may not be directly comparable to those in CHIS.
Although we had a sufficient number of observations to
standardize our sample based on age and education and
included only insured individuals in our analyses, addi-
tional standardization by potential confounding factors
such as race/ethnicity and type of health insurance was
not possible. Third, our study did not include at least one
variable found in previous research to influence the
receipt of preventive services: medical comorbidities [31].
Incorporating a measure of comorbidity in future studies
on the topic is therefore warranted. Fourth, our study did
not assess the specific reasons for not receiving preven-
tive services, and therefore we cannot determine whether
gaps in care are secondary to patient, provider or health
system factors. Finally, our data derive from self-report.
Previous studies have demonstrated that self-report is a
reasonable, although not perfect, proxy for various pre-
ventive health services [31,35-38].
Conclusions
Our findings demonstrate that there remains room for
improvement in the quality of care for two important cat-
egories of preventive service in SLE, particularly in
younger patients and those with lower educational attain-
ment. Although individuals in the LOS appear to receive
preventive services at frequencies similar to CHIS,
receipt of services in both groups is suboptimal. Given
the higher burden of infections and malignancies in SLE,
identifying strategies to abate these long-term outcomes
in SLE is an important goal. Coordinated, multidisci-
plinary care that involves generalist providers may offer
an opportunity to improve the provision of preventive
health services in SLE.
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